CL2010001634A1 - Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica. - Google Patents

Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.

Info

Publication number
CL2010001634A1
CL2010001634A1 CL2010001634A CL2010001634A CL2010001634A1 CL 2010001634 A1 CL2010001634 A1 CL 2010001634A1 CL 2010001634 A CL2010001634 A CL 2010001634A CL 2010001634 A CL2010001634 A CL 2010001634A CL 2010001634 A1 CL2010001634 A1 CL 2010001634A1
Authority
CL
Chile
Prior art keywords
nucleosides
hepatitis
preparation procedure
compounds derived
pharmaceutical composition
Prior art date
Application number
CL2010001634A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Original Assignee
Centocor Ortho Biotech Products L P
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001634(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Ortho Biotech Products L P, Medivir Ab filed Critical Centocor Ortho Biotech Products L P
Publication of CL2010001634A1 publication Critical patent/CL2010001634A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos derivados de nucleósidos, inhibidores del virus de la hepatitis C; procedimiento de preparación; composición farmacéutica que los comprende; y combinación farmacéutica.
CL2010001634A 2008-07-01 2010-12-30 Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica. CL2010001634A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08

Publications (1)

Publication Number Publication Date
CL2010001634A1 true CL2010001634A1 (es) 2011-08-05

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001634A CL2010001634A1 (es) 2008-07-01 2010-12-30 Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.

Country Status (29)

Country Link
US (1) US8431588B2 (es)
EP (1) EP2141172B1 (es)
JP (1) JP5624029B2 (es)
KR (1) KR20110038683A (es)
CN (2) CN102083845B (es)
AP (1) AP2010005505A0 (es)
AR (1) AR072428A1 (es)
AU (1) AU2009266004B2 (es)
BR (1) BRPI0913643A2 (es)
CA (1) CA2729316A1 (es)
CL (1) CL2010001634A1 (es)
CO (1) CO6321255A2 (es)
DK (1) DK2141172T3 (es)
EA (1) EA022754B1 (es)
EC (1) ECSP10010725A (es)
ES (1) ES2396803T3 (es)
HK (1) HK1226080A1 (es)
HR (1) HRP20121068T1 (es)
IL (1) IL209932A (es)
MX (1) MX2010014493A (es)
NI (1) NI201000231A (es)
PL (1) PL2141172T3 (es)
PT (1) PT2141172E (es)
SI (1) SI2141172T1 (es)
SV (1) SV2010003779A (es)
TW (1) TW201012814A (es)
UY (1) UY31950A (es)
WO (1) WO2010000459A1 (es)
ZA (1) ZA201009294B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240017125A (ko) * 2008-09-08 2024-02-06 사우디 아람코 테크놀로지스 컴퍼니 폴리카보네이트 폴리올 조성물
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
WO2013123138A2 (en) 2012-02-14 2013-08-22 University Of Georgia Research Foundation, Inc. Spiro [2.4]heptanes for treatment of flaviviridae infections
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
GEP20237457B (en) 2017-02-01 2023-01-10 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP2799442A1 (en) * 2002-06-28 2014-11-05 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
ATE490788T1 (de) * 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
DE602005015466D1 (de) * 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
EP2361922B1 (en) 2006-10-10 2012-08-22 Janssen Products, L.P. Intermediate to HCV-Nucleoside Inhibitors

Also Published As

Publication number Publication date
CN102083845A (zh) 2011-06-01
ECSP10010725A (es) 2011-04-29
SI2141172T1 (sl) 2013-02-28
JP5624029B2 (ja) 2014-11-12
AP2010005505A0 (en) 2010-12-31
IL209932A0 (en) 2011-02-28
UY31950A (es) 2010-01-29
PL2141172T3 (pl) 2013-03-29
EA022754B1 (ru) 2016-02-29
AR072428A1 (es) 2010-08-25
EP2141172A1 (en) 2010-01-06
ZA201009294B (en) 2012-06-27
US20110092460A1 (en) 2011-04-21
KR20110038683A (ko) 2011-04-14
EP2141172B1 (en) 2012-10-24
HRP20121068T1 (hr) 2013-01-31
CN105693794A (zh) 2016-06-22
SV2010003779A (es) 2011-02-08
IL209932A (en) 2013-12-31
CO6321255A2 (es) 2011-09-20
HK1226080A1 (zh) 2017-09-22
EA201170118A1 (ru) 2011-06-30
JP2011526270A (ja) 2011-10-06
NI201000231A (es) 2011-09-03
BRPI0913643A2 (pt) 2015-11-24
MX2010014493A (es) 2011-05-19
ES2396803T3 (es) 2013-02-27
WO2010000459A1 (en) 2010-01-07
TW201012814A (en) 2010-04-01
PT2141172E (pt) 2013-01-14
CN102083845B (zh) 2016-09-14
DK2141172T3 (da) 2013-01-21
US8431588B2 (en) 2013-04-30
AU2009266004B2 (en) 2014-01-30
AU2009266004A1 (en) 2010-01-07
CA2729316A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
DOP2013000185A (es) Compuestos antivirales
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
CO6761348A2 (es) Compuestos antivirales
CL2015000487A1 (es) Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
EA201190224A1 (ru) Ингибиторы гепатита c, содержащие конденсированные кольца
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
ECSP10010004A (es) Derivados de indol 2-carboxi sustituidos y métodos para su utilización
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
EA201170227A1 (ru) Имидазолкарбоксамиды
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.